FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

VITULLO NICOLE 		2. Issuer Name and Ticker or Trading Symbol

Celator Pharmaceuticals Inc [ NONE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/12/2016
(Street)

PRINCETON, NJ 08542
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/12/2016     D    2378924   D $30.25   0   I   By Domain Partners VI, L.P.   (1)
Common Stock   7/12/2016     D    16733   D $30.25   0   I   By DP VI Associates, L.P.   (1)
Common Stock   7/12/2016     D    5867   D $30.25   0   I   By Domain Associates, LLC   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to Purchase Common Stock   $5.2123   7/12/2016     D         44495    12/15/2011   12/14/2018   Common Stock   44495     (2) (3) 0   I   By Domain Partners VI, L.P.   (1)
Warrant to Purchase Common Stock   $5.2123   7/12/2016     D         32091    8/28/2012   8/27/2019   Common Stock   32091     (2) (4) 0   I   By Domain Partners VI, L.P.   (1)
Warrant to Purchase Common Stock   $3.58   7/12/2016     D         85777    4/29/2013   4/29/2020   Common Stock   85777     (2) (4) 0   I   By Domain Partners VI, L.P.   (1)
Stock Option (Right to Buy)   $3.116   7/12/2016     D         28000      (5) 6/3/2023   Common Stock   28000     (8) 0   D   (9)
 
Stock Option (Right to Buy)   $2.80   7/12/2016     D         14000      (6) 6/12/2024   Common Stock   14000     (8) 0   (10) D   (10)
 
Stock Option (Right to Buy)   $2.60   7/12/2016     D         14000      (7) 6/11/2025   Common Stock   14000     (8) 0   (10) D   (10)
 

Explanation of Responses:
( 1)  The Reporting Person is a Managing Member of (i) One Palmer Square Associates VI, LLC, which is the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P. and (ii) Domain Associates, LLC. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.
( 2)  Pursuant to the terms of a merger agreement among the Issuer, Jazz Pharmaceuticals plc ("Jazz") and a wholly-owned subsidiary of Jazz, and in accordance with the terms of the warrant agreements between the Issuer and Domain Partners VI, L.P., Jazz agreed to assume certain of the warrants (the "Assumed Warrants"), which following the closing of the merger were exercisable only for an amount in cash equal to (A) the merger consideration of $30.25 per share of Common Stock minus the exercise price of such warrants multiplied by (B) the number of shares of Common Stock underlying such warrants. The warrants not assumed by Jazz (the "Non-Assumed Warrants") were, following the closing of the merger, automatically terminated and converted into the right to receive only the value corresponding to (A) the merger consideration of $30.25 per share of Common Stock minus the exercise price of such warrants multiplied by (B) the number of shares of Common Stock underlying such warrants.
( 3)  Non-Assumed as to 26,600 Warrants and Assumed as to 17,895 Warrants.
( 4)  Assumed in full.
( 5)  The option as granted vested as follows: 9,334 shares on 6/03/2014 and the remainder in seven consecutive quarterly installments of 2,333 shares each, on the third day of each month, beginning on 9/03/2014 through 3/03/2016, and a final installment of 2,335 shares on 6/03/2016.
( 6)  The option as granted vests as follows: 4,666 shares on 6/12/2015 and the remainder in seven consecutive quarterly installments of 1,166 shares each, on the twelfth day of each month, beginning on 09/12/2015 through 3/12/2017, and a final installment of 1,172 shares on 6/12/2017.
( 7)  The option as granted vests as follows: 4,666 shares on 6/11/2016 and the remainder in seven consecutive quarterly installments of 1,166 shares each, on the eleventh day of each month, beginning on 09/11/2016 through 3/11/2018, and a final installment of 1,172 shares on 6/11/2018.
( 8)  Immediately prior to the effectiveness of the merger, each outstanding and unexercised option to purchase Common Stock of the Issuer was canceled and converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of (x) the merger consideration of $30.25 per share of Common Stock over (y) the exercise price per share underlying such option by (ii) the number of shares subject to such option immediately prior to the effectiveness of the merger.
( 9)  Pursuant to the limited liability company agreement of Domain Associates, LLC, proceeds from this stock option will be paid by the Issuer to Domain Associates, LLC.
( 10)  Pursuant to the limited liability company agreement of Domain Associates, LLC, proceeds from this stock option will be paid by the Issuer 50% to Domain Associates, LLC and 50% to the Reporting Person.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
VITULLO NICOLE
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542 		X



Signatures
/s/Lisa A. Kraeutler, Attorney-in-Fact 7/12/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Celator Pharmaceuticals Inc. (NASDAQ:CPXX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Celator Pharmaceuticals Inc. Charts.
Celator Pharmaceuticals Inc. (NASDAQ:CPXX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Celator Pharmaceuticals Inc. Charts.